Subscribe To

Price Alert Latest News Economic Calendar News

DARE / Daré Bioscience's One-Time Bacterial Vaginosis Treatment Scores FDA Approval

The FDA has approved Daré Bioscience Inc (NASDAQ: DARE) Xaciato (DARE-BV1) to treat bacterial vaginosis. Xaciato is a thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% designed as a one-time vaginally-administered treatment for bacterial vaginosis. Read More

Demo Live Account See Partner Details

Content Topics

Dar

Bioscience

One

Time

Bacterial

Vaginosis

Treatment

Bioscience s

One time

Scores

Approval

Stock

DARE

Posted: Dec 7 2021, 13:07

Author Name: Benzinga

DARE News

By Proactive Investors
July 13, 2023

Daré Bioscience's 'female Viagra' could be first-in-category product: broker

Daré Bioscience could have a first-in-category product on its hands with its “female Viagra” offering, analysts at Dawson James believe. The wome

By Seeking Alpha
May 11, 2023

Daré Bioscience, Inc. (DARE) Q1 2023 Earnings Call Transcript

Daré Bioscience, Inc. (NASDAQ:DARE ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Sabrina Martucci Johnson – Presi

By Seeking Alpha
March 30, 2023

Dare Bioscience, Inc. (DARE) Q4 2022 Earnings Call Transcript

Dare Bioscience, Inc. (NASDAQ:DARE ) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Sabrina Johnson - President & Chi

By Zacks Investment Research
November 15, 2022

Dare Bioscience, Inc. (DARE) Upgraded to Buy: What Does It Mean for the Stock?

Dare Bioscience, Inc. (DARE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This migh

By Seeking Alpha
November 10, 2022

Dare Bioscience, Inc. (DARE) Q3 2022 Earnings Call Transcript

Dare Bioscience, Inc. (NASDAQ:DARE ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Sabrina Johnson - President an

By Zacks Investment Research
November 10, 2022

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 27.27% and 100%, respectively, for the quarter ended September 2022. Do the n

By Seeking Alpha
May 12, 2022

Dare Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q1 2022 Results - Earnings Call Transcript

Dare Bioscience, Inc. (NASDAQ:DARE ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Sabrina Martucci Johnson - Presiden

By Seeking Alpha
March 31, 2022

Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q4 2021 Results - Earnings Call Transcript

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.